Bevaas

Bevacizumab

In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma.

Metastatic colorectal cancer (mCRC) 5 or 10 mg/kg IV infusion once every 2 wk, or 7.5 or 15 mg/kg once every 3 wk.

Hypersensitivity to Chinese hamster ovary cell products or recombinant human or humanised Ab. Patients w/ untreated CNS metastases. Pregnancy.

Hypersensitivity & infusion reactions. Discontinue use in patients w/ tracheoesophageal fistula or Grade 4 fistula; life-threatening (grade 4) venous thromboembolic events including pulmonary embolism; who experience Grade 3 or 4 bleeding during treatment. Increased risk of fistula development; haemorrhage especially tumour-associated haemorrhage. GI perforations; severe eye infections following compounding for unapproved intravitreal use; pulmonary hemorrhage/hemoptysis; HTN; posterior reversible encephalopathy syndrome; arterial & venous thromboembolism; CHF; neutropenia. Wound healing, necrotising fasciitis secondary to wound healing complications. Proteinuria. May affect ability to drive & use machines. Renal & hepatic impairment. May impair female fertility. Women of childbearing potential should use appropriate contraceptive measures. Not to be used during pregnancy. Not to be used during lactation for at least 6 mth following last dose of treatment. Not to be used in ped <18 yr.

Diarrhoea; asthenia. Anaemia, leukopenia, neutropenia, thrombocytopenia; cardiac failure, dyspnoea; abdominal distension & pain, constipation, dysphagia, gastritis, haematochezia, intestinal obstruction, mouth ulceration, nausea, proctalgia, rectal haemorrhage, stomatitis, vomiting; vertigo; hyperglycaemia; chest pain, decreased appetite, discomfort, fatigue, mucosal inflammation, pain, pyrexia; liver disorder; hyperglycaemia; bacterial infection, herpes zoster, lower resp tract infection, oral herpes, rash pustular, sepsis, UTI; increased ALT, AST, blood alkaline phosphatase, blood bilirubin, BP, transaminases & wt; decreased Hb, wt, lymphocyte, platelet & WBC count; decreased appetite, hyperlipidaemia, hypermagnesaemia; back pain, fasciitis, musculoskeletal chest pain, myalgia; burning sensation, headache, leukoencephalopathy, peripheral neuropathy, peripheral sensory neuropathy, seizure; aphasia; acute kidney injury, proteinuria; pneumonia; alopecia, palmar-plantar erythrodysaesthesia syndrome, skin hyperpigmentation; epistaxis.

Targeted Cancer Therapy

L01FG01 - bevacizumab ; Belongs to the class of VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors. Used in the treatment of cancer.

G